Vaccine (Adenoviral vector) · Immune activation, directed at human papillomavirus type 6 and 11 proteins · developed by Precigen
Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy that expresses a fusion antigen of selected regions of human papillomavirus 6 and 11 proteins. It is designed to generate an immune response against HPV 6 and HPV 11 proteins and is studied in recurrent respiratory papillomatosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 12, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06538480 | Phase 4 | Recurrent Respiratory Papillomatosis | Recruiting | PGEN |
| NCT07901738 | Phase 3 | Recurrent Respiratory Papillomatosis (RRP) | Not yet recruiting | PGEN |
| NCT04724980 | Phase 1/2 | Recurrent Respiratory Papillomatosis | Active not recruiting | PGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Juvenile-onset Recurrent Respiratory PapillomatosisPapillomaviridaePapillomavirus InfectionRecurrent Respiratory PapillomatosisRecurrent Respiratory Papillomatosis (RRP)
Updated Nov 15, 2026. Something wrong or missing? Report it on the PGEN page.
See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PGEN catalysts and pipeline →